The Competition and Markets Authority (CMA) will probe manufacturer Theramex’s purchase of “certain rights” to Femoston and Duphaston, two of Viatris’s hormone replacement therapy (HRT) drugs, it announced today (February 6).
The competition watchdog said that has today launched a merger inquiry to investigate the purchase to determine whether it would lead to a “substantial lessening of competition” in the UK.
Read more: CMA launches first phase inquiry into Pharmacy2U/LloydsDirect merger
In October, Theramex announced that it had reached an agreement with Viatris to buy the European rights to the two HRT treatments.
At the time, Theramex said that Viatris would retain the rights for Duphaston (dydrogesterone) and Femoston (estradiol/dydrogesterone) in Japan and Australia.
Read more: Hydrocortisone manufacturers face record £130m fine as appeal rejected
Then in December, Theramex announced that it had completed the purchase of the European rights to the two drugs, excluding the UK.
It said that its acquisition of Viatris’s UK rights to the products was “subject to regulatory approval”.
The CMA has invited comments on the purchase with a deadline of February 19.
Read more: ‘Abused dominant position': Appeal sees liothyronine manufacturer fined £41m
The deadline for the authority’s phrase one merger inquiry decision is April 4.
C+D approached Theramex and Viatris for comment.
This is a breaking news story. More to follow…
